Podcasts about rcc

Message from Terry Williams on June 14, 2026

07-06-2026- The Gospel of Luke- Luke 17:7-19- Matt Johnson by RCC

Message from Terry Williams on June 7, 2026

31-05-2026- The Gospel of Luke- Luke 17 : 1-6- Matt Johnson by RCC

Message from Jim Lewis on May 31, 2026

James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.

Tom Allen

24-05-2026 - Eternity - Hell - Luke 16:19-31 - Mark Wood by RCC

Message from Terry Williams on May 24, 2026

There's been a lot of talk in the past few years about how young men are leaving Protestant churches for the Roman Catholic Church. It's easy to forget that the Roman Catholic Church, like all other cults and false religions, uses carnal means and methods to cause those who are dead in their sins and trespasses to feel as if they are spiritually alive unto God. And because the RCC has been practicing and perfecting these techniques for over a thousand years, it is easy for people to forget that they are a corrupt institution through and through. In this episode, we want to focus on the many carnal means and techniques that the Roman Catholic Church uses to make its followers feel spiritual. Because the carnal man does not believe in an invisible God they give him a man who sits on a throne and wears a robe and a mitre and that is something the carnal man can believe in. Because the carnal man cannot imagine the glory of God they have built cathedrals so that a man can see the architecture and hear and feel the music and believe in the strength of man's hand instead of having to believe in The Invisible God. Because they cannot believe in the invisible work of prayer, they give you beads to hold in your hand and set prayers to pray over and over to make you feel spiritual. Instead of being able to approach God or their brothers and sisters in Christ and confess our sins they set up a confessional where you confess before a priest or an icon. Because they cannot believe in the spiritual nature of the church as the mother of us all, they give you Mary to worship as a mother, because people cannot believe that God is their father they tell them to call men their father which Jesus expressly forbade. Because they cannot understand God neither can they know him they give you a pantheon of saints you can choose to relate to and pray to instead of relating to the God you cannot see. They use every sense and artifice of man to create false worship, from images to incense to relics to holy places to icons. Because they have nothing but carnal means, they use every carnal method they can think of. The Roman Catholic Church is not unified, it is not holy, it is not spiritual. What it is great at, and what it has perfected over 1600 years, is making carnal men feel spiritual when they are truly headed to hell.Thumbnail image by Leonhard NiederwimmerTimecodes00:00:00 Appeal of Catholicism00:16:28 Corruption of Catholic Church00:28:25 Syncretism00:31:34 Schism00:34:56 Carnality00:48:59 Idolatry00:54:51 Vain Repetition01:04:27 Incense01:08:39 God's Word01:27:50 Church Fathers01:39:47 Sacred Secular01:57:17 ConclusionProduction of Reformation Baptist Church of Youngsville, NCPermanent Hosts - Dan Horn, Charles Churchill and Joshua HornTechnical Director - Timothy KaiserTheme Music - Gabriel Hudelson

There's been a lot of talk in the past few years about how young men are leaving Protestant churches for the Roman Catholic Church. It's easy to forget that the Roman Catholic Church, like all other cults and false religions, uses carnal means and methods to cause those who are dead in their sins and trespasses to feel as if they are spiritually alive unto God. And because the RCC has been practicing and perfecting these techniques for over a thousand years, it is easy for people to forget that they are a corrupt institution through and through. In this episode, we want to focus on the many carnal means and techniques that the Roman Catholic Church uses to make its followers feel spiritual. Because the carnal man does not believe in an invisible God they give him a man who sits on a throne and wears a robe and a mitre and that is something the carnal man can believe in. Because the carnal man cannot imagine the glory of God they have built cathedrals so that a man can see the architecture and hear and feel the music and believe in the strength of man's hand instead of having to believe in The Invisible God. Because they cannot believe in the invisible work of prayer, they give you beads to hold in your hand and set prayers to pray over and over to make you feel spiritual. Instead of being able to approach God or their brothers and sisters in Christ and confess our sins they set up a confessional where you confess before a priest or an icon. Because they cannot believe in the spiritual nature of the church as the mother of us all, they give you Mary to worship as a mother, because people cannot believe that God is their father they tell them to call men t

07-05-2026 - Eternity - Heaven - Luke 16:19-31 - Matt Johnson by RCC

Message from Terry Williams on May 17, 2026

Tom Scrivens

May 15, 2026 - Ashley Grayned of DPS 61, Andy Hynds of Richland Community College, and senior students, Alivia Bray, Jack Bush, Allie Allgeier, and Morriah Berglin, joined Byers & Co to talk about the Prep Academy where students are graduating from high school and RCC simultaneously. Listen to the podcast now!See omnystudio.com/listener for privacy information.

10-05-2026 - Eternity - Death - Luke 16-19-31 - Mark Wood by RCC

Message from Terry Williams on May 10, 2026

Deification: A secret in the Catholic Church that really shouldn't be a secret.  Join Dr. Gerry Crete, Dr Matthew Tsakanikas, professor of theology at Christendom College, and Dr. Peter for a wide-ranging discussion of the glory, the adventure, the awe of partaking of God's divine nature with the entirety of our being – our hearts, souls, minds, bodies, innermost selves, and all our parts, from a perspective informed by Internal Family Systems and grounded in a Catholic anthropology and metaphysics.  What does it really mean for all of you to be a beloved little son or beloved little daughter of God?  Books by Dr. Matthew Tsakanikas:2025 A Catechesis on Deification, Transfiguration & the Luminous Mysteries: https://www.amazon.com/dp/B0DX1HZMLM/2026 Meditations on Deification and the Luminous Mysteries: https://www.amazon.com/gp/aw/d/B0GWVYQGPPCheck out our sister podcast:  https://www.youtube.com/@ScriptureForYourInnerOutcasts The Resilient Catholics Community is about to reopen for new members in June. If you are a Catholic who wants to overcome the natural level obstacles to sharing deeply in God's divine nature as his beloved little son or beloved little daughter, and are into parts and systems thinking, consider applying to the RCC at www.soulsandhearts.com/rcc.Online Workshop for those Catholic Formators new to IFS, “Catholic Parts Work in Human Formation” will be on June 10, 2026 from 8:00 PM to 9:30 PM Eastern, register at https://members.soulsandhearts.com/Catholic-parts-workThe Formation for Formators Retreat is August 10-13, 2026 in Bloomington Indiana.  The theme is “Authentic Being and Authentic Relating.” This retreat focuses on you finding and loving you in more of your parts, including parts you have not yet encountered – your exiles – more at www.soulsandhearts.com/FFF  Conversation Hours with Dr. Peter are every Tuesday and Thursday from 4:30 PM to 5:30 PM Eastern Time on his cell at 317.567.9594 – it's an opportunity to discuss themes from this podcat or any of the materials generated by Souls and Hearts.  Key Moments12:00 What is deification/theosis/divinization?  Being made a son or daughter of God means sharing in God's nature.  15:00  Ephesians chapter 1 reveals God's plan from before the foundation of the world to makes us sons in the Son.  16:52  Dr. Gerry's objections to the IFS conceptualization of “Self”21:01 The image of God within us is dynamic – the “capax Dei” 21:50  How Adam and Eve lost their interior integration with the Fall and how Jesus opens the way for re-integration.27:05  Satan to Adam and Eve “Ye shall become like gods….” 30:30  How do we receive the love of God?  34:20  The internal battle: “Parts of me are drawn to receive God's love and parts of me are not…”41:19 The necessity of entering into a loving relationship with Jesus for interior integration43:40  God's wills that you flourish in all domains and in all your parts48:40  Divinization and the human body53:00  Divinization is “too hot to handle” for many Christians – but it's the essential framework for all of the Catholic life, it's the essential story that holds all the other stories.  1:02:00 The importance of accepting all of my parts as they are right now.  God accepts all parts as they are, so I need to as well.  Acceptance of a part does not mean endorsing that part's disordered desires, impulses, and emotions1:08:35  Sometimes parts find it easier to tolerate being loved by someone other than God at first, and that lesser loves can help parts open up to God's direct love1:25:01  Dr. Tsakanikas' key takeaway:  Love makes the lover want to make the beloved equal to himself,1:26:28  Dr, Gerry's takeaway:  It's important for us to evangelize each of our own parts1:27:54  Dr. Peter's takeaway:  Real love is given freely. But in our fallen human states, in our fallen human condition, it's not received without a cost to our parts. 

Message from Rodney Bartlett on May 3, 2026

RCC elder, Bob McDowell, shares how truly encountering the risen, Biblical Jesus always leads to transformation and a new identity rooted in Christ rather than in career, family, or personal achievements. Using the apostle Paul's dramatic conversion from persecutor to preacher—and his own testimony—Bob calls believers to surrender, embrace their new life in Christ, and step into the unique purpose and ministry God has prepared for them.

Thursday, 30 April 2026   For there are eunuchs who were born thus from their mother's womb, and there are eunuchs who were made eunuchs by men, and there are eunuchs who have made themselves eunuchs for the kingdom of heaven's sake. He who is able to accept it, let him accept it.” Matthew 19:12   Note: You can listen to today's commentary courtesy of our friends at the “Bible in Ten” podcast. (Click Here to listen)   You can also read this commentary, scrolling with music, courtesy of our friends at “Discern the Bible” on YouTube. (Click Here to listen), or at Rumble (Click Here to listen).   “For they are eunuchs who from mother's womb were born thus, and they are eunuchs who, they were eunuchized by men, and they are eunuchs who, they eunuchized themselves through the ‘kingdom, the heavens'. The ‘being able to contain' he contains.” (CG)   In the previous verse, Jesus told the disciples about those who could accept the premise concerning whether to marry or not. He next explains who those exceptions would be, beginning, “For they are eunuchs who, ‘from mother's womb' were born thus.”   A new word is seen here, the noun eunouchos, a eunuch. Strong's definition says, “a castrated person (such being employed in Oriental bed-chambers); by extension an impotent or unmarried man; by implication, a chamberlain (state-officer) -- eunuch.” The word is derived from eune, a bed, and echo, to have or hold. As such, the idea of “alone in bed” is understood.   Jesus' words of this first clause extend the idea of being a eunuch to a person born incapable of sex. Such a person is the first exception to the thought presented in the previous verse. Jesus continues, saying, “and they are eunuchs who, they were eunuchized by men.”   Another new word is seen, the verb eunouchizó, to eunuchize. It signifies making someone unable to procreate through mutilation or removal of the genitals (castration). The practice was once common. Today, it is much less common, but it has not died out. Religious cults and isolated subcultures still engage in the practice.   Further, sexual criminals are still castrated either through surgery or chemical castration. These are the second exception. The third category is noted as Jesus continues, “and they are eunuchs who, they eunuchized themselves through the ‘kingdom, the heavens'.”   This is the second and last use of the verb eunouchizó. As noted, the word extends beyond the standard idea of castration. It will figuratively be applied to those who don't engage in sexual activity for other reasons, including impotency or abstinence.   Some people are disciplined enough not to engage in sexual activity. They have placed something else above that aspect of life. In the case of acceptable self-denial, Jesus notes that there are those who have purposefully decided to pursue the kingdom of the heavens above marriage.   Paul was in this category. He refers to it in 1 Corinthians 7 and 1 Corinthians 9. He placed kingdom priorities above taking a wife. These are the three exceptions that are noted. The intent of Jesus' words is that, apart from these categories, marriage is the normally expected avenue for humanity. This is reflected in Jesus' final words on the matter, “The ‘being able to contain' he contains.”   In other words, if you fall into one of these categories, then your state is an acceptable exception to the original intent for humanity, which is to marry and remain married to your spouse.   Life application: In 1 Timothy 4, Paul says –   “Now the Spirit expressly says that in latter times some will depart from the faith, giving heed to deceiving spirits and doctrines of demons, 2 speaking lies in hypocrisy, having their own conscience seared with a hot iron, 3 forbidding to marry, and commanding to abstain from foods which God created to be received with thanksgiving by those who believe and know the truth. 4 For every creature of God is good, and nothing is to be refused if it is received with thanksgiving; 5 for it is sanctified by the word of God and prayer.” 1 Timothy 4:1-5   There are problems with forcing abstinence on others. First, it is contrary to the intent set forth for humanity as given in the first pages of Scripture. Second, it generally leads to other, more deviant side problems.   Paul's words in these verses are like an indictment on Roman Catholicism, penned in advance of the rise of that ideology. In order to serve the Lord as a “priest” or a “nun,” there must be a vow of abstinence, something not found in Scripture. It forces people to go against what is natural. That has led to sexual deviancy within their orders that is almost unmatched in any religion in history.   Homosexuality, molesting of children, violation of the “vows” between priests and lay people, or priests and the nunnery have filled Roman Catholicism since its inception. The RCC also commands that adherents abstain from certain foods at certain times, such as on certain days of the week.   These completely unbiblical practices set it off as the world's largest aberrant cult. Deviation from the Bible, either through allowing what it does not allow or commanding what it does not forbid, is wholly unacceptable. Be sure to stick with the Bible. Reject any teaching in any denomination or local church that does not comply with what the Bible presents.   Lord God, help us to know and apply Your precious word to our lives. May we not deviate from it. If we have had something contrary to what it teaches trained into us, help us to identify that precept and cut it out of our lives. May it be so to Your glory. Amen.

Message from Trace Kendrick on April 26, 2026

Message from Terry Williams on April 19, 2026

Matt Slick Live (Live Broadcast of 04/16/2026) is a production of the Christian Apologetics Research Ministry (CARM). Matt answers questions on topics such as: The Bible, Apologetics, Theology, World Religions, Atheism, and other issues! You can also email questions to Matt using: info@carm.org, Put "Radio Show Question" in the Subject line! Answers will be discussed in a future show. Topics Include: Matt Talks About Praying to The Saints/The Attributes of God, and How This Relates to Doctrines of The RCC and EO/ Can Sin and Demonic Disturbances Go Hand in Hand?/Problems with Creating Your Own Reality/ Why Do People Call Themselves Prophets?/ Matt Reads From His New Age Notebook/ April 16, 2026

Message from Terry Williams on April 12, 2026

In dieser Folge tauche ich gemeinsam mit Fabien Rossetti von RCC tief in die Welt der Prozessoptimierung für Autohäuser ein. Wir sprechen darüber, warum viele Betriebe auf einer wahren Schatzkiste sitzen und wie die Hauptschlagader im Unternehmen der Schlüssel zu mehr Effizienz, Kosteneinsparungen und Zukunftsfähigkeit wird. Fabien teilt praxisnahe Einblicke, warum lokale Optimierungen oft in Sackgassen führen und wie Prinzipien aus der Industrie – wie der One Piece Flow – echten Mehrwert im Autohaus schaffen. Ich hinterfrage, wie sich Branchenwissen übertragen lässt und warum Begeisterung für Veränderung heute wichtiger ist denn je. Wenn du wissen willst, wie dein Autohaus reibungslos wie ein Schweizer Uhrwerk laufen kann, ist diese Episode Pflichtprogramm.

Matt Slick Live (Live Broadcast of 04/8/2026) is a production of the Christian Apologetics Research Ministry (CARM). Matt answers questions on topics such as: The Bible, Apologetics, Theology, World Religions, Atheism, and other issues! You can also email questions to Matt using: info@carm.org, Put "Radio Show Question" in the Subject line! Answers will be discussed in a future show. Topics Include: Is Cremation Viable for The Christian?/ Political Leaders Getting Advice From Certain Christians/ Is Faith in God the Product of Regeneration?/ Current Events and Fulfilled Prophecy About Iran?/ What About the Three Days and Three Nights of Jesus' Prophecy?/ Can Women Conduct Radio Ministry?/ Why are Protestants Moving to The RCC and EO Churches?/ April 8, 2026

Welcome back to Grounded! Today the guys chat about their week, the weather and a great Easter weekend at RCC before unpacking the sermon from Easter Sunday. Thanks for listening and have a great week!

David Fleming speaks with Lee Ritenour... about his time with Steve Lukather... about a tune many associate with Jeff Beck... which originally came from Stevie Wonder. Also, a quick story about helping David Gilmour of all people out of a musical jam - he was stuck on where to go with the solo on one of Pink Floyd's MOST well-known tunes! Also - addressing the Ritenour release, Six-String Theory... which involves Lukather yet again!Also, Peter Curtis joins us once again to talk about SEVERAL outstanding concerts coming up through the RCC Department of Music guitar program... Triada Guitar Trio, jazz guitarist Mimi Fox, and several RCC ensembles. More at rccguitar.com, and more still at rcccoilschoolforthearts.comSO much in the world of guitar once again on the next KVC-Arts!

Message from Terry Williams on April 5, 2026

Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Monty Pal: Hello everyone and welcome to the ASCO Daily News Podcast. I'm your host, Monty Pal. I'm a medical oncologist, underline medical oncologist, a professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. You're going to understand why I underlined "medical oncologist" there. I'm actually on the line today with two amazing hematologists. Today, we're going to actually explore treatments for high-risk smoldering multiple myeloma following the FDA's approval last year of daratumumab for the first-ever treatment of this indication. Now, this is based on the AQUILA trial, and this represents a huge shift in our traditional watch-and-wait approach to active disease interception. We're going to consider whether this landmark trial published in The New England Journal translates to day-to-day practice. I think it does, and we'll certainly make an argument for that. And I'm so fortunate today to have two internationally acclaimed experts here in the conversation: Dr. Vincent Rajkumar, senior author on the manuscript, and Dr. Saad Usmani, also an expert in his own right in myeloma. Dr. Rajkumar is the lead investigator of the AQUILA study. He's a professor of medicine and consultant in the divisions of hematology and hematopathology at the Mayo Clinic in Rochester, Minnesota. He actually chairs the Myeloma, Amyloidosis, Dysproteinemia Program. He is also editor-in-chief of the Blood Cancer Journal. Dr. Usmani, he and I actually go way, way back. We actually did the AACR Molecular Biology in Clinical Oncology course, I want to say in 2006, so this is our 20-year anniversary, Saad. He's the chief of the myeloma service at the MSK Cancer Center and a professor of medicine at the Weill Cornell Medical College in New York.  Saad, Vincent, welcome. Dr. Saad Usmani: Thank you so much for having me, Monty. Dr. Vincent Rajkumar: Yeah, thanks, Monty. A pleasure to be here. Dr. Monty Pal: Thanks. And just a quick note for our listeners, all of our disclosures are available in the transcript of this episode. First off, Saad, did I get that right? Was it 2006 when we did that course together? Dr. Saad Usmani: Yeah, 20 years. We are coming up to our 20-year anniversary. It's remarkable to have seen our careers move the way they have, Monty. Dr. Monty Pal: Oh my gosh. And for all the fellows who are on the line, that AACR Molecular Biology and Clinical Oncology course, it's sometimes overlooked. Wonderful primer on translational science. Okay, now we're going to get to the heart of the matter here, the AQUILA trial. So this was a study, Vincent, that you led. I wonder if you'd walk us through the primary endpoints in the study. What are we looking at in the AQUILA trial specifically? Dr. Vincent Rajkumar: Thanks so much. Again, as you mentioned, smoldering multiple myeloma has just been a condition that we watch and wait. And the first thing that I want to clarify here is that the AQUILA trial is looking at only a subset of smoldering multiple myeloma. That is the high-risk smoldering multiple myeloma. It was defined the way high-risk smoldering myeloma was defined at the time the trial was designed. It randomized 390 patients. One arm got daratumumab single agent in an attempt to delay progression to active myeloma and possibly prolong survival. And the other arm was the traditional observation. The primary endpoint, therefore, was time to active multiple myeloma. Other endpoints included time to when patients needed to start therapy for active multiple myeloma, which can vary based on physician judgment, and overall survival. Of course, response rate, complete response rate, and others were also endpoints. Dr. Monty Pal: That's interesting. And you know, I wanted you to riff a little bit on this definition of high-risk smoldering myeloma. Can you tell our audience how that's sort of evolved over the years? Dr. Vincent Rajkumar: Yes. I mean, if you step back, monoclonal gammopathy of undetermined significance has only a 1% per year risk of progression. Smoldering multiple myeloma, all comers have a 10% per year risk of progression. And over the years, trials have been done in the whole population, and then more recently, we felt we should really focus on the people with high-risk smoldering, defined as a 50-50 risk of progression in 2 years. That's like a 25% per year risk of progression in the first 2 years, which is a very high risk for the patient and something that would justify prophylactic intervention. And that definition initially was based on just high levels of monoclonal protein like more than 3 grams, the IgA subtype of myeloma, the suppression of uninvolved immunoglobulins. Others have used bone marrow flow cytometry markers, cytogenetics. Those combinations of factors were available at the time the AQUILA trial was designed, and a select combination was used. Later on, we found that we could match almost all of that in a very simple risk stratification using just the percentage of bone marrow plasma cells, the level of the M-spike, and the free light chain ratio, all three of which are available to all patients with smoldering at the time of diagnosis. So you don't need any special testing. So more than 20% plasma cells, more than 20 for the light chain ratio, and more than 2 grams for the M-spike. If someone has any two of the three, that is high-risk smoldering multiple myeloma according to the IMWG, but that definition, of course, came in 2020 after the AQUILA trial completed accrual. Dr. Monty Pal: That's interesting because this sort of flips the traditional paradigm where biomarkers get more and more complex as time goes on. Am I right in saying this sort of simplifies things a little bit? It uses standard laboratory or clinical parameters to gauge this category? Dr. Vincent Rajkumar: Absolutely. People were using suppression of uninvolved immunoglobulins, and those levels are not standardized, often vary by race. Also, the other aspect was the abnormal plasma cells on flow cytometry. Again, labs define it differently. So this makes it much more simple. But the IMWG also did a separate exploratory cohort within that paper where we added cytogenetics and we added scoring systems to improve on this further. So it simplified it for regular clinical practice and for like trials. But if you have a patient in front of you, the IMWG paper also has more complex scoring systems where you can take more than 20; 21 is more than 20, so is 51. And so, you can use the actual numbers that a patient has, additional variables like cytogenetics, and get a more refined estimate of what is the true risk of progression. Dr. Monty Pal: That's really helpful. Now, you told us about the primary endpoints, you've helped us define high-risk smoldering myeloma. Can you give us a sense of the top-line results from AQUILA? Dr. Vincent Rajkumar: Yes, I think the most important one was the primary endpoint, time to multiple myeloma, was at 5 years, the progression-free survival was 63% in the daratumumab arm compared to 41% in the observation arm. So, you know, approximately 60% of patients in the observation arm had already progressed by 5 years. And that number was about 40% for the daratumumab arm. We also looked at time to starting myeloma therapy, which is clinically actually quite meaningful because, you know, myeloma therapy means patients get a quadruplet for induction, they get stem cell transplant, they get endless maintenance, they get ongoing therapy virtually for the entire duration. So, preventing the need for myeloma therapy is in and of itself, I think, a major endpoint. And that at 3 years, 40% of people in the observation arm required full myeloma therapy compared to only 20% in the daratumumab arm. So there's a significant reduction in the risk of developing active myeloma as well as the need for myeloma therapy by using a time-limited 3 years of daratumumab single agent. Dr. Monty Pal: Perfect summary of the results. And maybe, Saad, I'm going to bring you into the conversation now. How does this sort of influence your day-to-day practice for smoldering myeloma? Is this something that you've incorporated for that high-risk subset? Dr. Saad Usmani: Thank you, Monty, and I agree. I think that's a really nice summary from Vincent. This study is very important for several reasons. It's actually the third clinical trial that has demonstrated that patients who are in the high-risk smoldering myeloma category benefit from an early intervention that delays the progression to active myeloma or to end-organ damage. And so having a nuanced discussion with our patients in the clinic becomes very important. Having this discussion around as an option becomes very important. And like Vincent said, when we look at that high-risk smoldering myeloma patient population, someone who has 22, 23% plasma cells versus, you know, 45, 50, you know, it's going to be a different discussion each time. But I think it's a very important first step. And I think this sets up the stage for us to design clinical trials where we can ask other questions on what would be better than daratumumab alone in terms of delaying progression in these patients. The other thing that I do want to highlight, and Vincent touched upon this a little bit, that the treatment in this clinical trial was for a fixed duration of treatment. So it was not forever treatment. This is maybe something that Vincent, you can even comment on a little bit more because the question we get after having this discussion is, "Okay, what do we do with patients who are going to be progressing to active myeloma?" Whether we can utilize anti-CD38 therapies for those. So Vincent, I would love your take on this too. Dr. Vincent Rajkumar: Yeah, I think, you know, the main philosophical change for me was previously, the thing was 'don't treat', and now for high-risk smoldering multiple myeloma, the question is, is daratumumab the best treatment or can we do something better? And those trials are thankfully ongoing. One of them has already completed accrual, isatuximab-len-dex versus len-dex. And another one is ongoing in ECOG, almost close to finishing accrual. And in the future, we'll be trying to see if we can use early intervention to even cure and prevent progression altogether.  So we are in this phase where we have one approved regimen, one approved drug, and we are not sure whether we can improve on that. The question is, "is a myeloma-like therapy better than monotherapy" would be the next question, and then what would we do further beyond that? In this context, whenever we have patients like this, one of the questions that comes up, as Saad mentioned, is how does this affect newly diagnosed myeloma therapy if somebody has been treated for smoldering and things like that? How will they be considered for clinical trials? Would they be considered as relapse myeloma or still newly diagnosed myeloma? And those are important discussions for clinical trialists to keep in mind, but I think for clinical practice, your duty is to the patient in front of you. If they have high-risk smoldering myeloma and there's data that there's treatments that can delay progression significantly, delay the need for myeloma therapy significantly, that's the highest priority. We'll cross that bridge.   There are so few patients going on clinical trials right now that if such a patient were to later on progress and wants to enter in a newly diagnosed myeloma trial later, years later, we can figure that out later. I feel like the most important discussion is what to do for that patient today. I still prefer a clinical trial if one was available. If one was not available, I'd prefer early intervention, but have an informed discussion with the patient because some of them may wish to delay therapy still. Some of them may have very borderline numbers that you want to watch them closely. Some of them may be having other comorbidities that prevent need for therapy. Some of them maybe have had the smoldering for a long time and you already know it's stable. So a lot of factors go in, and I think it's not a one-size-fits-all. Dr. Monty Pal: This is a terrific discussion, and you know, it sort of segues into maybe a question around biology. And this is something I was going to get to a little bit later, but Saad, I'm glad you brought it up. I'll liken it to the only thing I know, which is kidney cancer. So, you know, in kidney cancer, we use checkpoint inhibitors as adjuvant therapy. And there's this question of whether or not it breeds some resistance in the localized setting to ultimately what the patient might potentially be exposed to in the metastatic setting. Tell me your thoughts on this, Vincent, then maybe Saad separately. If you treat a patient with daratumumab in this high-risk smoldering setting, could it theoretically sort of limit options in the refractory setting now that we have regimens like DRBD that are kind of being utilized, or daratumumab with teclistamab? Vincent, I'll throw that to you first. Dr. Vincent Rajkumar: This is a great question, and it's usually asked when we've done the lenalidomide trials actually. We try to put the question back. If that was your concern, how would you actually solve it? Is it really biology that's going to answer that? Or is it a randomized trial? So the experiment has been done three times now where early intervention has been given. And if there was some detriment because of that, that would be reflected in the overall survival. In all three trials, there's no such detriment seen. In the first lenalidomide-dex trial, there was an improvement in overall survival. In the AQUILA trial again, the confidence interval doesn't cross one, and patients had better long-term survival on AQUILA, but certainly not less. We've also examined PFS2 data, and that doesn't seem to be affected. So yes, there is a theoretical concern, and that concern cannot be allayed for new treatments which we have not even tried, like tec-dara, and whether that effect would be there or not. But so far, I don't see it. And I think the onus is on proof of that in order to prevent people from getting early therapy. Dr. Monty Pal: Yeah. Saad, your thoughts on that? And before you jump in, I'll mention, we're kind of taking the same approach in kidney cancer, we're trying to really do studies to see whether or not, you know, immunotherapy rechallenge in these contexts, you know, really lends any substantial benefit. So far, the results have been interesting. I don't think we have enough numbers as yet to capture the impact of adjuvant therapy as it translates to metastatic, but I see so many similarities between the scenarios that you're facing in myeloma and what we're facing in RCC. Saad, your thoughts? Dr. Saad Usmani: Thanks, Monty. I'll go back to something that Vincent alluded to a few minutes ago about the way that we risk-stratify patients within smoldering myeloma. Right now, we are relying more on a disease burden-based stratification looking at the percentage of plasma cells in the bone marrow, the monoclonal protein, as well as the involved light chain versus the uninvolved light chain ratio. However, there are efforts underway to actually incorporate genomics into that schema and try to refine that definition of high-risk smoldering. And there have been two papers that came out in the latter half of last year. In fact. Dr. Rajkumar and I are co-senior authors on one effort where we can identify genomic myeloma in patients in precursor conditions. One of the key things that came out of that effort was that within the high-risk smoldering myeloma category, about 90% of the patients are genomically myeloma. So this whole debate of whether we need to intervene for those patients, I think, you know, we have sufficient biologic evidence that yes, we need to intervene for those patients.  I think that the next real step, like Vincent stated, is how do we intervene in those patients? And those clinical trials kind of are ongoing. We will probably need to have more validation of those genomic models being incorporated, but that's what I see in the future. I wouldn't be concerned for the patients being seen today with that query about the disease biology evolving because if I'm seeing a patient today in March of the first quarter of 2026 and offering them monotherapy daratumumab in their high-risk smoldering situation for the next 3 years and then they progress to myeloma after another couple of years, we are talking about what would be the treatment options for them in 2031, 2032. So I think the field is moving so fast, we have a lot of novel therapies coming into that frontline setting rapidly, so our options at that time would be very different. So, you know, I just wanted to kind of set up the stage for saying, you know, our tools are getting better in delineating which patients will need that intervention. And then eventually, I think, you know, we'll have much better options for newly diagnosed myeloma patients at the time when they need it in the future. Dr. Monty Pal: Just absolutely brilliant, absolutely brilliant. I love that summary. I think that you're absolutely right in saying that, you know, you've got to think about what you're going to do for that patient sort of in the moment, what's going to optimize their outcome and agree that the landscape is evolving very rapidly.  I'd be remiss, Saad, if I didn't ask you about something that I've been following in terms of your career trajectory. You've developed quite a reputation for your leadership in trials looking at CAR T-cell therapies for myeloma. Can you give us a sense of where that stands in broad terms? Dr. Saad Usmani: Certainly, Monty. I think the CAR Ts have slowly made their way from late relapse to early relapse. And now we have clinical trials that have completed accrual in the frontline setting comparing them to standard-of-care treatment for both older myeloma patients or transplant-ineligible patients, as well as younger transplant-eligible patients where we're actually trying to replace transplants with BCMA-directed CAR T-cell therapies. The nuance there would be we want to equal or better the survival outcomes that we've accomplished without compromising on the safety side of things for patients. Those therapies are moving into earlier lines. And more excitingly, you know, that's just the first wave of CARs. The next wave of CAR technology is coming, and it's going to be in vivo CARs where we may not need lymphodepleting chemotherapy, we may not even need as stringent regulatory nuances that we do for cellular therapies today. So, you know, I think the field is moving rapidly, and it's going to be a very interesting landscape to see over the next 5 to 6 years. Dr. Monty Pal: Yeah, you know, it's so interesting. I know in the solid tumor space, we're trying to replicate the success that you've had with CAR T and bispecifics, and I do see some light at the end of the tunnel. I'm seeing some really promising agents being developed, but clearly, we have so much to learn from our colleagues in hematology. Well, I have to tell you, this has just been a phenomenal conversation. Vincent, congratulations on your leadership of the AQUILA trial. Clearly, a big paradigm shift in the field. Saad, thank you for offering your expert insights and really giving us also a glimpse at the future of myeloma. Really appreciate having you both on the podcast today. Dr. Vincent Rajkumar: Thank you, Monty. Dr. Saad Usmani: Thank you so much. Dr. Monty Pal: And thank you so much to our listeners for your time today. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:      Dr. Monty Pal    @montypal   Dr. Vincent Rajkumar @VincentRK Dr. Saad Z. Usmani @szusmani   Follow ASCO on social media:           ASCO on X     ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview      Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical    Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis    Dr. Vincent Rajkumar: Honoraria: Research to Practice, Medscape Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date Dr. Saad Usmani: Consulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, Abbvie, Bristol-Myers Squibb/Celgene, Regeneron, AstraZeneca, Sanofi Research Funding: Janssen Oncology, Bristol-Myers Squibb, K36 Therapeutics, Abbvie, Regeneron  

Matt Slick Live (Live Broadcast of 03/30/2026) is a production of the Christian Apologetics Research Ministry (CARM). Matt answers questions on topics such as: The Bible, Apologetics, Theology, World Religions, Atheism, and other issues! You can also email questions to Matt using: info@carm.org, Put "Radio Show Question" in the Subject line! Answers will be discussed in a future show. Topics Include: Matt Discusses his Work on Faith and Works, and The Error of The RCC and EO/ Spiritual Warfare/Can Demons Influence Christians?/ What About College Fraternities and Sororities?/ What About Cultural Items- Dreamcatchers, Crystals, etc.?/ Were Any of The Crusades Justified?/ Who Gets Eternal Life?/Is Eternal Suffering Necessary?/ A Caller Asks About an Indian Ministry called "Jesus Ministries"/ March 30, 2026

Message from Rodney Bartlett on March 29, 2026

Welcome back to the Oncology Brothers podcast! In this episode, we discussed current treatment landscape and updates from GU ASCO 2026, with focus on kidney cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by Dr. Katy Beckermann, a medical oncologist from Tennessee Oncology, to discuss: The current standard of care for renal cell carcinoma (RCC), including adjuvant treatment options post-surgery. The implications of the KEYNOTE-564 study and the approval of Pembrolizumab for high-risk RCC patients. Insights from the LITESPARK- 022 trial, comparing Pembrolizumab with the combination of Pembrolizumab and Belzutifan in the adjuvant setting. The challenges of undertreatment versus overtreatment in kidney cancer therapy, including side effects and financial toxicity. Strategies for managing metastatic disease, including re-challenging immunotherapy and the role of IMDC criteria in treatment decisions. The promising data from LITESPARK-011, exploring the combination of Lenvatinib and Belzutifan in the second-line setting. Tune in for an informative discussion that covers the latest research, clinical practices, and expert opinions in the field of kidney cancer. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology! #KidneyCancer, #RenalCellCarcinoma, #GUASCO2026, #OncBrothers

Assumptions are one of the most common ways we manage anxiety in relationships, but they also keep us stuck in the very patterns we're trying to heal. In this episode, Vanessa Bennett, LMFT is joined by Madeleine Downey, RCC to unpack how mind-reading, overfunctioning, and “being the bad guy in someone's story” often come from early beliefs rooted in shame. They walk through a practical loop you can use in real time—belief → assumption → behavior → confirmation—and why bringing “the story I'm telling myself is…” into the light can diffuse conflict and deepen intimacy. This is a relational invitation to stop living inside imagined certainty and start choosing clarity, vulnerability, and responsibility.Additional ResourcesExplore: VanessaBennett.comBook: The Motherhood MythCommunity: Inner Compass CollectiveTraining: Inner Compass AcademyConnect with Inner CompassFollow on InstagramConnect with Vanessa Bennett:Follow on InstagramFollow on TikTokLearn more on SubstackConnect with Vanessa Bennett on LinkedInSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to spotlight the most practice-informing data to come out of the 2026 Genitourinary Cancers Symposium.In prostate cancer, the phase 3 PEACE-3 trial (NCT02194842) demonstrated a clear overall survival (OS) benefit with the combination of radium-223 and enzalutamide (Xtandi) compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). The phase 2 BRCAAway trial (NCT03012321) showed that for patients with mCRPC with BRCA1/2 or ATM mutations, combination therapy with olaparib (Lynparza) and abiraterone led to a longer median progression-free survival (PFS) than sequential treatment. Additionally, the POSEIDON meta-analysis indicated that short-term hormone therapy is adequate for most patients with prostate cancer receiving postoperative radiotherapy, as longer durations did not improve OS.In bladder cancer, the phase 3 KEYNOTE-B15 trial (NCT04700124) showed that neoadjuvant enfortumab vedotin-ejfv (Padcev) combined with pembrolizumab (Keytruda) significantly improved OS and event-free survival vs neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer, despite notable toxicities like skin and ocular adverse effects. Furthermore, the phase 2 RC48G001 trial (NCT04879329) found that disitamab vedotin (RC48) generated responses in patients with metastatic urothelial carcinoma, including those with HER2-low expression.Regarding renal cell carcinoma (RCC), the phase 3 LITESPARK-011 trial (NCT04586231) showed a PFS benefit with belzutifan plus lenvatinib vs cabozantinib in the second-line setting. In the adjuvant setting, the phase 3 LITESPARK-022 study (NCT05239728) demonstrated that adding belzutifan (Welireg) to pembrolizumab improved disease-free survival vs placebo plus pembrolizumab in patients with resected clear cell RCC.Finally, regarding testicular cancer, a phase 2 trial (NCT04876456) of cabozantinib showed meaningful activity in patients with relapsed/refractory germ cell tumors. Drs Armstrong and Tawagi noted that this marks the first nonchemotherapy agent to demonstrate such clinical benefit in this population, providing a new option for patients who have exhausted traditional treatment regimens.

This week's episode will be focusing on a recap of some of the important data ASCO GU just held in San Francisco end of February. We will go over some topics in prostate, RCC, bladder cancer, and other GU tumors. 

Message from Aaron Lewis on March 22, 2026

Ross Sullivan remains one of the most debated and mysterious suspects in the Zodiac Killer case. In this episode, we explore the evidence linking Sullivan to both the infamous Zodiac murders and the earlier 1966 killing of Cheri Jo Bates at Riverside City College.Sullivan, a library assistant at RCC, was present on campus at the time of Bates' murder and later drew suspicion from co-workers who described him as unsettling and potentially dangerous. His sudden disappearance following the killing, combined with a change in appearance, raised further questions.We break down the key elements of the case:The Cheri Jo Bates murder and its possible connection to ZodiacWitness accounts and co-worker suspicionsThe disturbing “desktop poem” and its alleged link to Zodiac writingsSullivan's interest in cryptography and handwriting disguisePhysical similarities to the Zodiac composite sketchThe controversial Mikado connectionConflicting alibi claims and institutionalisation recordsBut the case against Sullivan is far from airtight. We also examine the major weaknesses:A significant height discrepancy with eyewitness descriptionsFingerprints that reportedly did not match crime scene evidenceClaims of hospitalisation during key Zodiac attacksThe lack of formal investigation by law enforcementExpert Review: Simon & Tom Analyse the EvidenceFormer investigators Simon and Tom provide a critical breakdown of the Sullivan theory, questioning whether modern researchers may now have a broader view of the case than original investigators ever did.They raise important questions about Sullivan's mental health history, including what may have triggered his diagnoses and whether this is relevant to assessing his potential for violence.The discussion challenges a common assumption: that Sullivan's cremation prevents DNA analysis. Tom explains how familial DNA could still be used to eliminate or potentially link him through relatives.However, both experts stress a key limitation—existing Zodiac DNA samples may not be reliable enough for definitive identification, meaning DNA may be more useful for elimination than confirmation.They also highlight the importance of forensic integrity, noting that any evidence must have a clear chain of custody to stand up in court.The height discrepancy is debated, with Simon viewing it as a major issue, while Tom argues eyewitness estimates—especially at night—are often unreliable.Crucially, Tom warns against “linking assumptions”—building a case on the idea that Bates is a Zodiac victim, then linking Sullivan to Bates, which compounds uncertainty.Both agree that much of the suspicion around Sullivan originates from co-workers rather than law enforcement, raising questions about how seriously he was ever investigated.The conclusion: Sullivan is an intriguing suspect with some compelling overlaps—but the case remains circumstantial and far from proven.With no confirmed DNA and conflicting evidence, the question remains open: was Ross Sullivan a viable suspect overlooked by police—or another compelling but ultimately flawed theory?In the next episode, we turn to another major Zodiac suspect: Lawrence Kane.About Crime Time Inc.Season 5 of Crime Time Inc. broadens its reach across two sides of the Atlantic.This season features cases from Scotland and across the wider UK — rooted in real investigative experience — alongside deep dives into some of the most infamous murder cases in American history.Hosted by former detectives Simon and Tom, with experience in both the UK and the United States, including time working alongside the FBI, the show strips away sensationalism to explain how crime and justice really work.Two crime worlds. One podcast.New episodes released regularly throughout the season.Our Website: https://crimetimeinc.com/If you like this show please leave a review. It really helps us.Please help us improve our Podcast by completing this survey.http://bit.ly/crimetimeinc-survey Hosted on Acast. See acast.com/privacy for more information.

Matt Slick Live (Live Broadcast of 03/17/2026) is a production of the Christian Apologetics Research Ministry (CA RM). Matt answers questions on topics such as: The Bible, Apologetics, Theology, World Religions, Atheism, and other issues! You can also email questions to Matt using: info@carm.org, Put "Radio Show Question" in the Subject line! Answers will be discussed in a future show. Topics Include: Matt Talks About a Logic Method He Uses for Sola Scriptura/Ungodly Practice of RCC and The EO/ A Quick Analysis of Mary Kay Baxter/ Is LORD a Name?/Matt Explains Hebrew Language Characteristics/ Another Extended Interaction About Water Baptismal Methodology/ A Call of Encouragement for Matt/ Private Praying in Tongues, is it Biblical?/ Reading/Studying Demonology, Should We?/ March 17, 2026

Tom and Brian take the stage in London for a live podcast. With the help of several special guests from the audience, they discuss management of peri-operative therapy in bladder cancer (notably in patients who may refuse cystectomy) and also the emerging pembro plus belzutifan data in adjuvant RCC.

Matt Slick Live (Live Broadcast of 03/16/2026) is a production of the Christian Apologetics Research Ministry (CA RM). Matt answers questions on topics such as: The Bible, Apologetics, Theology, World Religions, Atheism, and other issues! You can also email questions to Matt using: info@carm.org, Put "Radio Show Question" in the Subject line! Answers will be discussed in a future show. Topics Include: Matt Discusses a Recent Church Experience/A Self Examination Leading to A Call to Unity/ A Caller is Having Trouble Keeping His Mind on Christ, Matt Gives Advice/ Was King David Responsible for His Many Wives and The Resulting Effects?/ A Caller Asks About Atheists' Views on Evidence for God/ Eternal Security-Denied by The RCC and The EO/ March 16, 2026

Message from Aaron Lewis on March 15, 2026

In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas, medical oncologist from the Fred Hutch Cancer Center, who walked through practice-changing and practice-reinforcing data across bladder cancer, kidney cancer, and prostate cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics discussed included: CREST & POTOMAC: IO-BCG combination data in high-risk BCG-naive NMIBC, both demonstrating a hazard ratio of 0.68 for DFS / EFS. EV-304/KEYNOTE-B15: established EV-Pembrolizumab as the new perioperative standard of care for resectable muscle-invasive bladder cancer regardless of cisplatin eligibility, with a pathological complete response rate of 56% and overall survival hazard ratio of 0.65. LITESPARK-022 & LITESPARK-011: data exploring Belzutifan combinations in adjuvant and refractory RCC settings, while managing key toxicities of anemia and hypoxia. CAPITELLO-281: evaluating capivasertib in PTEN-deficient metastatic hormone-sensitive prostate cancer, where patient related outcomes were reported.  Join us for this comprehensive discussion covering the latest GU oncology advances that will directly impact your clinical practice. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #GUASCO2026, #BladderCancer, #RenalCellCarcinoma, #ProstateCancer, #OncBrothers

Message from Terry Williams on March 8, 2026

Message from Terry Williams on March 1, 2026

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium, noting presentations to watch at sessions on prostate cancer, bladder cancer, and renal cell carcinoma (RCC).For prostate cancer, the experts revealed that they're looking forward to seeing updated results from the phase 3 PEACE-3 trial (NCT02194842) of enzalutamide (Xtandi) plus radium-223 in patients with metastatic castration-resistant prostate cancer (mCRPC), noting that bone-protecting agents are mandatory for patients receiving radium-223. They also pointed to overall survival data from the phase 2 BRCAAway trial (NCT03012321) of abiraterone (Zytiga) plus prednisone and olaparib (Lynparza) for patients with mCRPC harboring BRCA or ATM alterations. Additionally, they spotlighted the phase 3 PEACE 2 trial (NCT01952223), which explores moving chemotherapy into the localized prostate cancer setting.Regarding bladder cancer, they identified the phase 3 KEYNOTE-B15 trial (NCT04700124) as a potentially practice-changing trial evaluating perioperative enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in cisplatin-eligible patients with muscle-invasive bladder cancer. They also noted that circulating tumor DNA data are a significant trend, appearing in several clinical trials to guide response-adapted management.For RCC, the hosts highlighted the phase 3 LITESPARK-011 (NCT04586231) and LITESPARK-022 (NCT05239728) trials, which are evaluating the HIF-2α inhibitor belzutifan (Welireg) in different RCC populations. They also emphasized the importance of the CLIMATE study (ACTRN12622000247774) for detecting residual disease in patients with testicular cancer.

Message from Trace Kendrick on February 22, 2026

Message from Terry Williams on February 15, 2026

This week, Courtt and Rima are back on the mic (virtually, mind you) with tired eyes, strong opinions, and zero tolerance for hater behavior. From snowy streets and parking stress to champagne pours and borrowed Jack Daniels LOL, Episode 207 kicks off exactly how you'd expect: real life first, music and mess immediately after. The girls catch up on work, fatigue, winter blues, and the struggle of leaving the house when parking is on the line. Then it's time to pour up and get into what really matters the Grammys, aka our Super Bowl. And surprisingly? Nobody's mad.We break down standout wins, performances, and speeches, including Duran Bernard's well-deserved Grammy moment, Kehlani's continued rise, and why some artists just know when they're in their bag. There's deep appreciation for authenticity, longevity, and artists who stay true to themselves while still winning. Of course, it wouldn't be RCC without side commentary: confusion over new artists, debates about breath control, and very strong feelings about tributes, vocals, and who understood the assignment. Lauryn Hill's tribute sparks thoughtful (and slightly chaotic) conversation, while performances from Lucky Daye, Leon Thomas, and others get their flowers.   What We Get Into: Virtual recording chaos and tired-girl energy Snow, parking stress, and why leaving the house is a risk Pour-up check: champagne vs. Jack Daniels Grammy wins that actually made sense Duran Bernard's journey and long-overdue recognition Kehlani's Grammy moment and musical evolution Album pacing, artist rollouts, and letting music breathe Performances, vocals, and who really understood the assignment Lauryn Hill's tribute and honoring legends properly New artists, breath control debates, and musical curiosity Red Cup Rule of the week: stop being a hater     The Soundtrack: Muni Long  - Delulu Tone Stith - Waiting on You   Say HI to kidz on Social: Rima IG| just.karima_ Court IG| keepinitcourtt Pod IG| rccpod Rate, and Review on Apple Podcast  Website: https://www.redcuppod.com Email: Redcuppod@gmail.com